Atlas Invest | $25,000,000 | (Jan 22, 2026)
AiStrike | $7,000,000 | (Jan 22, 2026)
Zarminali Pediatrics | $110,000,000 | (Jan 22, 2026)
SAMABRIVA
France
- Amiens, Hauts-de-France
- 13/12/2023
- Unknown
- $4,313,000
Samabriva Biotechnology is a company that is creating a new method for producing biopharmaceuticals, chemicals, and biotech products using plants. Samabriva’s flexible platform combines the benefits of plant-based systems and traditional biomanufacturing techniques. By developing and cultivating high-yield plant clones in large-scale bioreactors it is possible to produce large quantities of high-value products more efficiently than traditional manufacturing methods.
- Industry Biotechnology Research
- Website https://samabriva.com/
- LinkedIn https://www.linkedin.com/company/samabriva/about/
Related People
Marina GuilletFounder
France -
Greater Nantes Metropolitan Area
Samabriva Biotechnology is a company that is creating a new method for producing biopharmaceuticals, chemicals, and biotech products using plants. Samabriva’s flexible platform combines the benefits of plant-based systems and traditional biomanufacturing techniques. By developing and cultivating high-yield plant clones in large-scale bioreactors it is possible to produce large quantities of high-value products more efficiently than traditional manufacturing methods.
Statusphere | $18,000,000 | (Jan 21, 2026)
BrightInsight | $13,000,000 | (Jan 21, 2026)
Think Bioscience | $55,000,000 | (Jan 21, 2026)
ErVimmune | $19,917,795 | (Jan 21, 2026)
Formulary Financial | $4,600,000 | (Jan 21, 2026)
Ultra Pouches | $11,000,000 | (Jan 21, 2026)
XBuild | $19,000,000 | (Jan 21, 2026)
Dam Secure | $4,000,000 | (Jan 21, 2026)
Infinitopes | $15,400,000 | (Jan 21, 2026)